Edition:
United States

Sol Gel Technologies Ltd (SLGL.OQ)

SLGL.OQ on NASDAQ Stock Exchange Global Market

6.80USD
25 Sep 2018
Change (% chg)

-- (--)
Prev Close
$6.80
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
4,357
52-wk High
$16.47
52-wk Low
$6.03

Latest Key Developments (Source: Significant Developments)

Sol-Gel Announces Collaborative Agreement With Perrigo
Wednesday, 15 Aug 2018 04:05pm EDT 

Aug 15 (Reuters) - Sol Gel Technologies Ltd ::SOL-GEL TECHNOLOGIES ANNOUNCES COLLABORATIVE AGREEMENT FOR GENERIC PRODUCT WITH PERRIGO.SOL GEL TECHNOLOGIES - ENTERED COLLABORATIVE AGREEMENT WITH PERRIGO ISRAEL, AFFILIATE OF PERRIGO.SOL GEL TECHNOLOGIES - AGREEMENT FOR DEVELOPMENT, MANUFACTURING AND COMMERCIALIZATION OF GENERIC PRODUCT CANDIDATE.SOL GEL TECHNOLOGIES - PERRIGO TO CONDUCT REGULATORY, SCIENTIFIC, CLINICAL ACTIVITIES NECESSARY TO DEVELOP GENERIC PRODUCT.SOL GEL TECHNOLOGIES - IF APPROVED BY FDA, PERRIGO AGREED TO COMMERCIALIZE GENERIC PRODUCT CANDIDATE IN U.S..  Full Article

Sol-Gel Technologies Reported Loss Of $5.7 Million For Q1
Tuesday, 15 May 2018 04:05pm EDT 

May 15 (Reuters) - Sol Gel Technologies Ltd ::SOL-GEL TECHNOLOGIES REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS.SOL GEL TECHNOLOGIES LTD - REPORTED A LOSS OF $5.7 MILLION FOR Q1 OF 2018, COMPARED TO A LOSS OF $5.6 MILLION FOR SAME PERIOD IN 2017.  Full Article

Sol-Gel Technologies Announces Pricing Of IPO
Wednesday, 31 Jan 2018 07:48pm EST 

Jan 31 (Reuters) - Sol Gel Technologies Ltd ::ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING.‍PRICING OF ITS INITIAL PUBLIC OFFERING OF 6.3 MILLION ORDINARY SHARES AT A PUBLIC OFFERING PRICE OF $12.00 PER ORDINARY SHARE​.  Full Article

Sol Gel Technologies Sees IPO Of 5 Mln Ordinary Shares
Tuesday, 23 Jan 2018 06:20am EST 

Jan 23 (Reuters) - Sol Gel Technologies Ltd ::SOL GEL TECHNOLOGIES LTD SEES IPO OF 5.0 MILLION ORDINARY SHARES PRICED BETWEEN $11.00 AND $13.00 PER ORDINARY SHARE - SEC FILING.SOL GEL TECHNOLOGIES LTD SAYS INTENDS TO USE ABOUT $26.0 MILLION OF IPO PROCEEDS TO FUND PLANNED PHASE III CLINICAL TRIALS FOR TWIN FOR TREATMENT OF ACNE.SOL GEL TECHNOLOGIES-INTENDS TO USE ABOUT $20 MILLION OF IPO PROCEEDS TO FUND PLANNED PHASE III CLINICAL TRIALS FOR VERED FOR TREATMENT OF SUBTYPE II ROSACEA.  Full Article